Table 1 Summary of the included studies
A.Studies included in prognostic evaluation and/or association evaluation | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study ID | MiR-212 type | Country | Sample size | Cancer type | Stage | Specimen | Control | Follow-up (months) | Assay | Cut-off point | Experiment type | NOS score | Survival results |
Meng, X. 2013 [31] | miR-212 | China | 180 | CRC | I-III | Tissue | Normal tissue | 96 | RT- qPCR | Median | In vitro, in vivo | 10 | OS, DFS |
Qi, B. 2014 [32] | miR-212 | China | 46 | EC | 0-III | Tissue | Normal tissue | 96 | RT-qPCR | Median | – | 8 | OS |
Dou, C. 2015 [33] | miR-212 | China | 95 | HCC | I-IV | Tissue | Normal tissue | 60 | RT-qPCR | Mean | In vitro, in vivo | 10 | OS, DFS |
Li, D. 2015 [34] | miR-212 | China | 71 | GC | 0-IV | Tissue | Normal tissue | 120 | RT-qPCR | Median | In vitro, in vivo | 8 | OS |
Tu, H. 2015 [35] | miR-212 | China | 86 | HCC | I-IV | Tissue | Normal tissue | 60 | RT-qPCR | Median | In vitro | 10 | OS, DFS |
Gu, C. 2017 [36] | miR-212 | China | 60 | RCC | I-IV | Tissue | Normal tissue | 60 | RT-qPCR | Mean | In vitro, in vivo | 9 | OS, RFS |
Jiang, C. 2017 [37] | miR-212 | China | 73 | NPC | I-IV | Tissue | Normal tissue | 60 | RT-qPCR | Median | – | 10 | OS, DFS |
Lu, Z. 2017 [38] | miR-212-5p | China | 125 | TNBC | NR | Tissue | Normal tissue | 136 | RT-qPCR | NR | In vitro, in vivo | 10 | OS, DFS |
Tang, T. 2017 [39] | miR-212 | China | 115 | NSCLC | I-IV | Tissue | Normal tissue | 60 | RT-qPCR | Median | In vitro | 9 | OS |
Wu, Z. 2017 [40] | miR-212 | China | 45 | PDAC | I-IV | Tissue | Normal tissue | 36 | FISH | Median | – | 8 | OS |
Zhou, Y. 2017 [41] | miR-212 | China | 58 | PCa | NR | Tissue | Normal tissue | NA | RT-qPCR | NR | In vitro, in vivo | 9 | NA |
Qu, H. 2018 [42] | miR-212 | China | 72 | PCa | NR | Tissue | Other individuals | 156 | RT-qPCR | Median | In vitro | 9 | OS |
Tong, Z. 2018 [43] | miR-212 | China | 48 | RCC | I-IV | Tissue | Normal tissue | NA | RT-qPCR | Mean | In vitro | 9 | NA |
Wang, F. 2018 [44] | miR-212 | China | 80 | HCC | I-IV | Serum | Other individuals | 36 | RT-qPCR | Median | – | 9 | OS |
Chen, J. 2019 [45] | miR-212-3p | China | 83 | HCC | I-III | Tissue | Normal tissue | 66 | RT-qPCR | Median | – | 10 | OS, RFS |
Mou, T. 2019 [46] | miR-212 | China | 53 | CRC | I-IV | Tissue | Normal tissue | 60 | RT-qPCR | Median | In vitro | 10 | OS |
Yue, H. 2019 [47] | miR-212 | China | 41 | PDAC | I-IV | Tissue | Normal tissue | 25 | RT-qPCR | Middle of the range | In vitro | 10 | OS |
Azar, M. 2020 [48] | miR-212 | Iran | 30 | TSCC | I-IV | Tissue | Normal tissue | NA | RT-qPCR | NR | – | 10 | NA |
Kang, Y. 2020 [49] | miR-212 | China | 30 | NPC | I-IV | Tissue | Normal tissue | NA | RT-qPCR | NR | In vitro | 10 | NA |
Shao, J. 2020 [50] | miR-212 | China | 110 | GC | I-IV | Serum | Other individuals | 53 | RT-qPCR | Median | In vitro | 10 | OS |
Yuan, Z. 2020 [51] | miR-212-3p | China | 90 | HCC | I-IV | Tissue | Normal tissue | 60 | RT-qPCR | NR | In vitro | 9 | OS |
Zhang, L. 2020 [52] | miR-212-3p | China | 63 | HGSOC | I-IV | Tissue | NR | 130 | RT-qPCR | Median | - | 9 | OS, DFS |
B Studies included in diagnostic evaluation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Study ID | miR-212 type | Country | Cancer type | Stage | Normalizer | Control source | Assay | Sample type | AUC (95% CI) | Cancer |
Miah, S. 2012 [53] | miR-212 | UK | BC (UCC) | pTa- pT4 | NR | Healthy individuals | qRT-PCR | Urine | NR | Higher miR |
Cote, G. 2014 [54] | miR-212 | USA | PDAC | I-IV | NR | CP or BBD | qRT-PCR | Plasma | 0.9 | Higher miR |
Bile | 0.981 | Higher miR | ||||||||
Ramalinga, M. 2015 [55] | miR-212 | USA | Pca | NR | NR | Healthy individuals | qRT-PCR | Serum | 0.66 (0.53–0.78) | Lower miR |
Bagheri, A. 2016 [56] | miR-212 | Iran | NSCLC | I-IV | ncRNAs | Healthy individuals | qRT-PCR | Sputum | 0.69 (0.53–0.85) | Lower miR |
Tissue | 0.62 (0.47–0.77) | NR | ||||||||
Damavandi, Z. 2016 [57] | miR-212 | Iran | BrC | I-III | 5srRNA | Normal tissue | qRT-PCR | Tissue | 0.63 | Lower miR |
Wang, F. 2018 [44] | miR-212 | China | HCC | I-IV | cel-miR-39 | Healthy individuals | qRT-PCR | Serum | 0.706 (0.63–0.73) | Lowe r miR |
Pu, X. 2020 [58] | exmiR-212-3p | China | PC | I-IV | NR | Healthy individuals | TCLN biochip | Peripheral blood plasma | 0.599 | NR |
Shao, J. 2020 (50) | miR-212 | China | GC | I-IV | NR | Healthy individuals | qRT-PCR | Serum | 0.96 | Lower miR |